Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ATNM.

Investigation Details

On August 5, 2024, Actinium issued a press release “announcing a regulatory update on the Company’s planned Biologics License Application (‘BLA’) filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML’).” According to the Company, the FDA has “determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint[.]” Following this news, Actinium stock dropped almost 60% on the same day.

What's Next?

If you are aware of any facts relating to this investigation or purchased Actinium securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ATNM. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240818305973/en/